MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Gynecologic Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

915 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
915 works in the cohort · of 4,299,418page 17 of 19

Labels cover 0 of 915 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 915 of 915 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa, a novel engineered cytokine, in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (326)
Thomas J. Herzog, Kathleen N. Moore, Panagiotis A. Konstantinopoulos, Lucy Gilbert, John L. Hays, Bradley J. Monk +9 more
2022· article· en· Gynecologic Oncology· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
Corrigendum to “Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: Society of Gynecologic Oncology and American Society for reproductive medicine evidence-based review” [Gynecol. Oncol. 155 (2019) 508–514]
Lee-may Chen, Stephanie V. Blank, Elizabeth M. Burton, Karen Glass, Emily R. Penick, Terri L. Woodard
2020· erratum· en· Gynecologic Oncology· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
Efficacy and safety of tisotumab vedotin versus investigator's choice of chemotherapy in second-line or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT-cx12/GOG-3057): A global, randomized, open-label, phase III study
Brian M. Slomovitz, Antonio González‐Martín, Keiichi Fujiwara, Elsa Kalbacher, Andrea Bagaméri, Leslie M. Randall +14 more
2024· article· en· Gynecologic Oncology· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
To the editor
C. Blake Gilks, Amy Jamieson, Jessica N. McAlpine, Naveena Singh
2023· letter· en· Gynecologic Oncology· Medicine
machine prediction:candidate · noneconsensus · none
0
citations

How this was built: Screen · Findings · About